Cargando…

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

BACKGROUND: The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markovic, Uros, Romano, Alessandra, Del Fabro, Vittorio, Bellofiore, Claudia, Bulla, Anna, Parisi, Marina Silvia, Leotta, Salvatore, Gentile, Massimo, Cangialosi, Clotilde, Vincelli, Iolanda, Mineo, Giuseppe, Rossi, Marco, Poidomani, Massimo, Uccello, Giuseppina, Maugeri, Cinzia, Mannina, Donato, Innao, Vanessa, Di Raimondo, Francesco, Conticello, Concetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982826/ https://www.ncbi.nlm.nih.gov/pubmed/33763359 http://dx.doi.org/10.3389/fonc.2021.624405

Ejemplares similares

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
por: Conticello, Concetta, et al.
Publicado: (2019)

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
por: Del Fabro, Vittorio, et al.
Publicado: (2023)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
por: Romano, Alessandra, et al.
Publicado: (2022)

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
por: Parisi, Marina Silvia, et al.
Publicado: (2019)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS-COV2 BREAKTHROUGH INFECTION
por: Romano, A., et al.
Publicado: (2022)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
por: Duminuco, Andrea, et al.
Publicado: (2023)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Duminuco, A., et al.
Publicado: (2023)

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis
por: Bonello, Francesca, et al.
Publicado: (2019)

Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience
por: Duminuco, Andrea, et al.
Publicado: (2023)

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost
por: Milone, Giuseppe, et al.
Publicado: (2020)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
por: Narsipur, Nihal, et al.
Publicado: (2021)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
por: Duminuco, Andrea, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
por: Calafiore, Valeria, et al.
Publicado: (2020)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
por: Morabito, Fortunato, et al.
Publicado: (2022)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Daratumumab-induced transient myopic shift
por: Mavrommatis, Maria A., et al.
Publicado: (2018)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab for immune thrombotic thrombocytopenic purpura
por: van den Berg, Jana, et al.
Publicado: (2022)

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_077mgki11udamttqtn5200io19